Dr. Krishna C. Alluri, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 555
Licensed in Texas since 2022, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license T6810 (first issued 2022; active) · FL license ME106470 · ID license M11347 -
Internal Medicine Physician
FL license ME106470 -
Specialist
FL license ME106470
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospital San Antonio, TX
- Baptist Medical Center San Antonio, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 555
- Services billed
- 86,728
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 8,881 | 76 |
| Injection, iron sucrose, 1 mg | 6,500 | 13 |
| Injection, fosaprepitant, 1 mg | 4,950 | 14 |
| Injection, denosumab, 1 mg | 1,500 | 15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,135 | 32 |
| Injection, granisetron hydrochloride, 100 mcg | 600 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 592 | 249 |
| Injection, palonosetron hcl, 25 mcg | 580 | 23 |
| Insertion of needle into vein for collection of blood sample | 383 | 133 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 374 | 131 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in San Antonio, TX | 175 |
| Dexamethasone Other prescribers in San Antonio, TX | 54 |
| Letrozole Other prescribers in San Antonio, TX | 53 |
| Tamoxifen Citrate Other prescribers in San Antonio, TX | 41 |
| Prednisone Other prescribers in San Antonio, TX | 31 |
| Hydroxyurea Other prescribers in San Antonio, TX | 30 |
| Revlimid (lenalidomide) | 30 |
| Eliquis (apixaban) Other prescribers in San Antonio, TX | 29 |
| Alendronate Sodium Other prescribers in San Antonio, TX | 25 |
| Ondansetron Hcl Other prescribers in San Antonio, TX | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 9 payments worth $295 in total to this clinician.
| AbbVie Inc. | $125 |
|---|---|
| Janssen Biotech, Inc. | $31.96 |
| Pfizer Inc. | $30.65 |
| Pharmacosmos Therapeutics Inc. | $28.27 |
| Tempus Ai, Inc | $27.77 |
| Regeneron Healthcare Solutions, Inc. | $21.68 |
| Daiichi Sankyo Inc. | $17.96 |
| Gilead Sciences, Inc. | $12.42 |
| Food and Beverage | $252 |
|---|---|
| Education | $43.07 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 11, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
| Gilead Sciences, Inc. Dec 3, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4222250;G360;11234979 | $12.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $305,736 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adeno…
AstraZeneca Pharmaceuticals LP - A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Jazz Pharmaceuticals Inc. - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung …
Amgen Inc. - A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable kras G12C…
Eli Lilly and Company - A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung…
Amgen Inc. - A phase iii, randomized, double-blind study of tira plus atezo in adjuvant nsclc
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.